What is the thyroid cancer percentage risk linked to Mounjaro?

Why does the thyroid cancer question exist for Mounjaro at all?

The worry traces back to pre-approval animal research. When rodents were given GLP-1 receptor agonists (the class of drug that includes tirzepatide) at high doses over a prolonged period, some developed tumours of the thyroid C-cells. C-cells produce calcitonin, and malignant C-cell tumours are what we call medullary thyroid carcinoma.

The critical caveat is species biology. Rodent C-cells are far more densely packed with GLP-1 receptors than human C-cells are. Many researchers and regulators consider the animal findings a poor model for what happens in people. The Mounjaro Summary of Product Characteristics on the eMC discusses this directly: it acknowledges the rodent data, notes the uncertain relevance to humans, and states that no causal link to human thyroid cancer has been established.

What this means practically is that the precautionary warning exists because regulators are doing their job, not because human patients have developed thyroid cancer at a measurable rate in trials. The SURMOUNT programme involved thousands of adults followed for up to 72 weeks, and you can read a detailed breakdown of what the evidence shows on the question of thyroid cancer and tirzepatide if you want to go further into the data. That is reassuring, though it does not mean the question is entirely closed; longer-term post-marketing surveillance continues.

Who is Mounjaro genuinely not suitable for on thyroid grounds?

This is where the caution is absolute and clinical. Anyone with a personal history of medullary thyroid carcinoma should not take Mounjaro. The same applies to people with MEN2, a genetic condition that predisposes carriers to MTC as well as other endocrine tumours. These are listed contraindications in the UK licence, not soft warnings.

A common misconception worth addressing gently: some people assume the thyroid warning means the medicine is risky for thyroid conditions in general, including hypothyroidism or Hashimoto's disease. That is not what the data says. The specific concern is C-cell tumours (medullary cancer), which is a distinct and relatively rare thyroid cancer type. If you take levothyroxine for an underactive thyroid, the MTC contraindication does not automatically apply, but your prescriber needs to know your full thyroid history to make a proper assessment. You can read more about what thyroid history means for eligibility on our page covering how Mounjaro may relate to thyroid function.

Prescribers at regulated services check for contraindications before anything is approved. A named clinician (not an automated system) reads your consultation answers and your medical history as part of that process.

What does ongoing monitoring look like in practice?

Mounjaro's Black Triangle status means Eli Lilly and the MHRA are required to submit and review safety data on a rolling basis. Patients and healthcare professionals can contribute to this by reporting any suspected side effects, including unexpected thyroid symptoms, through the MHRA Yellow Card scheme. This is not a formality, real-world reporting has shaped understanding of GLP-1 medicines since they came to market, and the thyroid question is one the system is specifically watching.

In routine clinical practice, there is no recommendation to screen all tirzepatide users for thyroid cancer before or during treatment, the evidence does not support population-wide monitoring. What is recommended is that you tell your prescriber about any thyroid symptoms that are new or worsening: a lump or swelling in the neck, unexplained hoarseness, trouble swallowing, or difficulty breathing. These should be assessed without delay rather than attributed to the medicine and ignored.

For a fuller picture of how tirzepatide works and what conditions shape suitability, our Mounjaro overview covers the licensed use and clinical background in plain terms. Details about the SURMOUNT trial findings and the question of historical reports are on our page addressing whether anyone has developed thyroid cancer on Mounjaro.

What should you do if you have thyroid concerns and are considering Mounjaro?

Talk to a clinician before starting. If you have a personal or family history of MTC or MEN2, Mounjaro is not the right route and a prescriber will tell you so. If your thyroid history is something else (treated hypothyroidism, a previous benign nodule, a family member with non-medullary thyroid cancer) the picture is more nuanced, and our guide to Mounjaro and thyroid considerations sets out the key factors that shape a prescriber's assessment of your circumstances.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber the same day it is submitted. They assess contraindications including thyroid history as a standard part of the process. If there is any uncertainty, they will decline to prescribe and advise you to speak to your GP or a specialist, because getting this right matters more than completing a transaction. The dedicated page on Mounjaro and thyroid cancer goes deeper into the mechanism and clinical guidance if you want more detail before your consultation.

If you have questions about a specific health situation before starting, our clinical team is available seven days a week. And if you are ready to take the next step, a free consultation with our prescribers is the place to begin.